MX2022006558A - Anticuerpos anti-influenza b neutralizantes y usos de los mismos. - Google Patents

Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Info

Publication number
MX2022006558A
MX2022006558A MX2022006558A MX2022006558A MX2022006558A MX 2022006558 A MX2022006558 A MX 2022006558A MX 2022006558 A MX2022006558 A MX 2022006558A MX 2022006558 A MX2022006558 A MX 2022006558A MX 2022006558 A MX2022006558 A MX 2022006558A
Authority
MX
Mexico
Prior art keywords
influenza
antibodies
virus
neutralizing anti
neutralizing
Prior art date
Application number
MX2022006558A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Ebony Benjamin
Nicole Kallewaard-Lelay
Josephine Mary Mcauliffe
Leslie Wachter
Andy Yuan
Qing Zhu
Davide Corti
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2022006558A publication Critical patent/MX2022006558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

La invención se refiere a anticuerpos y fragmentos de unión a antígeno de los mismos que pueden unirse a la hemaglutinina (HA) del virus de la influenza B y neutralizar virus de la influenza B en dos linajes distintos desde un punto de vista filogenético. En una modalidad, el anticuerpo o fragmento de unión a antígeno puede unirse a la hemaglutinina del virus de influenza B y neutralizar virus de la influenza B en linajes Yamagata y Victoria.
MX2022006558A 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos. MX2022006558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15

Publications (1)

Publication Number Publication Date
MX2022006558A true MX2022006558A (es) 2022-07-11

Family

ID=55079157

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017000595A MX2017000595A (es) 2014-07-15 2015-07-14 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2022006558A MX2022006558A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2022006561A MX2022006561A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017000595A MX2017000595A (es) 2014-07-15 2015-07-14 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006561A MX2022006561A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Country Status (10)

Country Link
US (5) US10294292B2 (es)
EP (1) EP3169407A4 (es)
JP (3) JP6837434B2 (es)
CN (3) CN113563462A (es)
AU (3) AU2015289805B2 (es)
BR (1) BR112017000640A2 (es)
CA (1) CA2954780A1 (es)
MX (3) MX2017000595A (es)
RU (2) RU2739952C2 (es)
WO (1) WO2016011035A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733244A1 (en) * 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
RS62446B1 (sr) 2015-06-01 2021-11-30 Medimmune Llc Neutrališući vezujući molekuli protiv gripa i njihova primena
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
EP4051707A1 (en) * 2019-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Anti-hemagglutinin antibodies and methods of use thereof
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US6027459A (en) 1996-12-06 2000-02-22 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1167382A1 (en) * 1999-03-31 2002-01-02 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
AU2001234125A1 (en) 2000-02-22 2001-09-03 Medical And Biological Laboratories Co., Ltd. Antibody library
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
EP3569610A3 (en) 2000-12-12 2020-03-18 Medlmmune, LLC Molecules with extended half lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
KR101133910B1 (ko) 2003-07-23 2012-04-13 후지레비오 가부시키가이샤 항-인플루엔자 ａ형 바이러스 모노클로날 항체 및 상기항체를 이용하는 면역 측정 기구
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
WO2007109742A2 (en) 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
AU2007249160B2 (en) * 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
KR101485197B1 (ko) 2006-09-07 2015-01-23 크루셀 홀란드 비.브이. 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
KR101474227B1 (ko) 2006-10-02 2014-12-18 리제너론 파아마슈티컬스, 인크. 사람 ｉｌ-4 수용체에 대한 고친화성 사람 항체
AU2007325872B2 (en) 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
RU2553325C2 (ru) 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
CA2821492A1 (en) 2010-12-13 2012-06-21 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
HUE051756T2 (hu) 2011-07-18 2021-03-29 Inst Res Biomedicine Influenza A vírus elleni semlegesítõ antitestek és alkalmazásuk
JP6498439B2 (ja) 2011-09-20 2019-04-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
EP2793945B1 (en) * 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
US8834881B2 (en) * 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
EP3461501A1 (en) 2012-11-13 2019-04-03 F. Hoffmann-La Roche AG Anti-hemagglutinin antibodies and methods of use
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
AU2015289805B2 (en) * 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
RS62446B1 (sr) 2015-06-01 2021-11-30 Medimmune Llc Neutrališući vezujući molekuli protiv gripa i njihova primena
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus

Also Published As

Publication number Publication date
MX2022006561A (es) 2022-07-11
CN113563462A (zh) 2021-10-29
JP7209754B2 (ja) 2023-01-20
WO2016011035A8 (en) 2016-12-08
AU2020233635B2 (en) 2024-01-18
JP2021074013A (ja) 2021-05-20
US20200190169A1 (en) 2020-06-18
US11787853B2 (en) 2023-10-17
JP7453430B2 (ja) 2024-03-19
US11174304B2 (en) 2021-11-16
RU2020100073A3 (es) 2020-06-10
US20240076357A1 (en) 2024-03-07
BR112017000640A2 (pt) 2017-11-14
JP2023052268A (ja) 2023-04-11
AU2024202231A1 (en) 2024-05-02
CA2954780A1 (en) 2016-01-21
EP3169407A4 (en) 2018-04-25
US10294292B2 (en) 2019-05-21
RU2020100073A (ru) 2020-03-03
AU2015289805A1 (en) 2017-03-02
US20170218054A1 (en) 2017-08-03
US10519221B2 (en) 2019-12-31
RU2711932C2 (ru) 2020-01-23
JP6837434B2 (ja) 2021-03-03
RU2017104638A (ru) 2018-08-15
JP2017523805A (ja) 2017-08-24
CN106573154A (zh) 2017-04-19
CN113173990A (zh) 2021-07-27
AU2020233635A1 (en) 2020-10-08
US20190233504A1 (en) 2019-08-01
WO2016011035A3 (en) 2016-03-10
RU2739952C2 (ru) 2020-12-30
MX2017000595A (es) 2017-10-12
AU2015289805B2 (en) 2020-06-25
WO2016011035A2 (en) 2016-01-21
EP3169407A2 (en) 2017-05-24
RU2017104638A3 (es) 2019-07-17
CN106573154B (zh) 2021-06-15
US20220025020A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
AU2024202231A1 (en) Neutralizing anti-influenza b antibodies and uses thereof
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
EA202092435A3 (ru) Моноклональные антитела против bcma
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
MX2019007921A (es) Nuevos agentes de union a ha.
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
PH12016502535A1 (en) Interferon alpha and omega antibody antagonists
MX2017015189A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
EA201891445A1 (ru) Молекулы антител, которые связываются с tnf-альфа
MX2018009218A (es) Anticuerpos de cgrp y sus usos.